<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203384</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0913-PR-0038</org_study_id>
    <nct_id>NCT01203384</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects</brief_title>
  <acronym>CT02</acronym>
  <official_title>Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CERESPIR</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CERESPIR</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of multiple oral doses of CHF5074 in young healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from Screening through Day 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose linearity of CHF5074 plasma levels (Cmax)</measure>
    <time_frame>Day -1 through Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose linearity of CHF5074 plasma levels (AUC 0-t)</measure>
    <time_frame>Day -1 through Day 18</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CHF5074 1x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF5074 2x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF5074 3x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, oral tablet, multidose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF5074 1x</intervention_name>
    <description>oral tablet, 1x, once a day in the morning for 14 days</description>
    <arm_group_label>CHF5074 1x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF5074 2x</intervention_name>
    <description>oral tablet, 2x, once a day in the morning for 14 days</description>
    <arm_group_label>CHF5074 2x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF5074 3x</intervention_name>
    <description>oral tablet, 3x, once a day in the morning for 14 days</description>
    <arm_group_label>CHF5074 3x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet, placebo, once a day in the morning for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is judged to be in good health on the basis of medical history, complete
             physical examination including vital signs, 12-lead electrocardiogram (ECG) and
             standard laboratory tests.

        Exclusion Criteria:

          -  Medical history (within the last 10 years) of major cardiovascular, hepatic or renal
             disease.

          -  Abnormal results of liver function tests, renal function tests or thyroid tests
             performed at screening.

          -  Significant allergic conditions that require medical treatment

          -  Use of any psychoactive, recreational or prescription drug within the 4 weeks prior to
             study drug administration.

          -  Use of ibuprofen, sulindac sulfide, indomethacin, flurbiprofen within 2 weeks prior to
             study drug administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy L Shenouda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iberica Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Iberica Clinical Research Center</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

